celecoxib has been researched along with Atherogenesis in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the present drug evaluation article, the authors elucidate the role of celecoxib, a selective COX-2 inhibitor, in the treatment of atherosclerosis." | 8.93 | Celecoxib for the treatment of atherosclerosis. ( Briasoulis, A; Charakida, M; Papageorgiou, N; Tousoulis, D; Zacharia, E, 2016) |
| " To clarify the role of COX-2 in atherosclerosis, we conducted a study to test whether the COX-2 inhibitor, celecoxib, prevents the development and progression of the atherosclerotic process." | 7.74 | The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice. ( Jacob, S; Lanza-Jacoby, S; Laury-Kleintop, L, 2008) |
| "In the present drug evaluation article, the authors elucidate the role of celecoxib, a selective COX-2 inhibitor, in the treatment of atherosclerosis." | 4.93 | Celecoxib for the treatment of atherosclerosis. ( Briasoulis, A; Charakida, M; Papageorgiou, N; Tousoulis, D; Zacharia, E, 2016) |
| " At this time, celecoxib is the only available COX-2-specific inhibitor for treatment of pain and inflammation." | 3.85 | COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages. ( Carsons, SE; De Leon, J; Gomolin, IH; Kasselman, LJ; Littlefield, MJ; Reiss, AB; Voloshyna, I, 2017) |
| "Atherosclerosis being considered as an inflammatory disorder, the present study was undertaken to investigate the effectiveness of anti-inflammatory drugs (ibuprofen, aspirin, and celecoxib) in hypercholesterolemia." | 3.74 | Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study. ( Dabhi, JK; Mehta, A; Solanki, JK, 2008) |
| " To clarify the role of COX-2 in atherosclerosis, we conducted a study to test whether the COX-2 inhibitor, celecoxib, prevents the development and progression of the atherosclerotic process." | 3.74 | The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice. ( Jacob, S; Lanza-Jacoby, S; Laury-Kleintop, L, 2008) |
| "The risk of adverse cardiovascular events in humans is increased with chronic use of cyclooxygenase-2 (COX-2) inhibitors." | 1.35 | Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice. ( Gitlin, JM; Loftin, CD, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, L | 1 |
| Li, J | 1 |
| Yi, J | 1 |
| Liu, H | 1 |
| Lei, H | 1 |
| Grimm, H | 1 |
| Kretzschmar, J | 1 |
| Cook, MD | 1 |
| Brown, MD | 1 |
| Papageorgiou, N | 1 |
| Zacharia, E | 1 |
| Briasoulis, A | 1 |
| Charakida, M | 1 |
| Tousoulis, D | 1 |
| Voloshyna, I | 1 |
| Kasselman, LJ | 1 |
| Carsons, SE | 1 |
| Littlefield, MJ | 1 |
| Gomolin, IH | 1 |
| De Leon, J | 1 |
| Reiss, AB | 1 |
| Dabhi, JK | 1 |
| Solanki, JK | 1 |
| Mehta, A | 1 |
| Gitlin, JM | 1 |
| Loftin, CD | 1 |
| Raval, M | 1 |
| Frank, PG | 1 |
| Laury-Kleintop, L | 2 |
| Yan, G | 1 |
| Lanza-Jacoby, S | 2 |
| Romero, FI | 1 |
| Martínez-Calatrava, MJ | 1 |
| Sánchez-Pernaute, O | 1 |
| Gualillo, O | 1 |
| Largo, R | 1 |
| Herrero-Beaumont, G | 1 |
| Kang, HJ | 1 |
| Oh, IY | 1 |
| Chung, JW | 1 |
| Yang, HM | 1 |
| Suh, JW | 1 |
| Park, KW | 1 |
| Kwon, TK | 1 |
| Lee, HY | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Koo, BK | 1 |
| Kang, WY | 1 |
| Kim, W | 1 |
| Rha, SW | 1 |
| Bae, JH | 1 |
| Chae, IH | 1 |
| Choi, DJ | 1 |
| Kim, HS | 1 |
| Nissen, SE | 1 |
| Steffel, J | 1 |
| Akhmedov, A | 1 |
| Fähndrich, C | 1 |
| Ruschitzka, F | 1 |
| Lüscher, TF | 1 |
| Tanner, FC | 1 |
| Jacob, S | 1 |
1 review available for celecoxib and Atherogenesis
| Article | Year |
|---|---|
Celecoxib for the treatment of atherosclerosis.
Topics: Animals; Atherosclerosis; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans | 2016 |
1 trial available for celecoxib and Atherogenesis
| Article | Year |
|---|---|
Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atherosclerosis; Blood Pressure; Celecoxib; Coronar | 2012 |
10 other studies available for celecoxib and Atherogenesis
| Article | Year |
|---|---|
Dose-Effect of Irbesartan on Cyclooxygenase-2 and Matrix Metalloproteinase-9 Expression in Rabbit Atherosclerosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Atheroscle | 2018 |
The Effects of Exercise, Aspirin, and Celecoxib in an Atherogenic Environment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Celecoxib; Cells, Cultured; Epopr | 2018 |
COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Biological Transport; Celecoxib; Cell Adhe | 2017 |
Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study.
Topics: Animals; Anti-Inflammatory Agents; Antiparasitic Agents; Aspirin; Atherosclerosis; Celecoxib; Diseas | 2008 |
Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2009 |
Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Celecoxib; Chemokine CCL2; Cyclooxygenase | 2010 |
Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Atherosclerosis; Cachexia; Celecoxib; Cyclo | 2010 |
Cox-2 inhibitors and cardiovascular disease: considerable heat, but not much light.
Topics: Atherosclerosis; Celecoxib; Coronary Restenosis; Cyclooxygenase 2 Inhibitors; Female; Humans; Male; | 2012 |
Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Celecoxib; Cell Line; Endothelium, Vascula | 2006 |
The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2008 |